Rooted in China, focusing on global major cancers

First/best-in-class drug developer with US and China IND approvals and global clinical trial track record

Focusing on prostate cancer, breast cancer and liver cancer with blockbuster drug potential

De-risked and comprehensive product pipeline

High-profile management team

Founding and core team having decades of experience in R&D and entrepreneurship in the US with complementary strength and R&D capabilities

Homepage 2018-06-05T05:25:06+00:00

Company Highlights

Comprehensive product pipeline underscored by
a sound product development strategy

- 8 drug candidates in the pipeline, ranging from preclinical trial stage products to Ph. III clinical trial products
- Proprietary R&D + licensing-in
- Best-in-class drugs with established target spots + first-in-class drugs with novel target spots

Focus on major cancer TAs, addressing huge unmet market demand

- Focus on prostate cancer, breast cancer and liver cancer
- >US$10bn addressable market for each TA
- Key products targeting two high risk diseases, CRPC and TNBC

A First-class R&D platform for small molecule drugs in China

- Design and synthesis of active molecules
- In vitro/animal model efficacy test
- Pharmacokinetics study